Zoetis Inc.

Zoetis Inc.

ZTSNYSE / NASDAQHealthcareLarge cap

$79.11-$1.68 (-2.1%)

Last close · Data as of Nov 20, 2026

Market cap
$33.3B
P/E
12.5x
EV / EBITDA
9.9x
Revenue
$9.5B
Net margin
28.2%
ROCE
29.0%

-31.7% over the last year

Zoetis Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-1.2%
3M
+5.5%
6M
-0.8%
1Y
-31.7%
5Y
-65.1%

52-week range

Day change -$1.68 (-2.1%) from $81 to $79 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in ZTS, bought on each weekday since 2021.

News & filings

What Zoetis filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthOperating margin of 38.0% against a peer median of 20.4%.

Concerns (1)

  • The price is 12.5% below its 200-day average, and the 50-day average is below the 200-day.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally.

Read moreShow less

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.

Sector
Healthcare
Shares outstanding
424.9M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$33.3B
P/E
12.5x
P/B
10.0x
EV / EBITDA
9.9x
EV / Sales
4.3x
P/S
3.5x
52-week high
$131.10
52-week low
$69.10

Profitability

Operating margin
38.0%
Net margin
28.2%
EBITDA margin
43.0%
ROE
80.2%
ROCE
29.0%
ROA
17.3%
Asset turnover
0.61

Growth

Revenue
$9.5B
Revenue growth, 1Y
2.3%
Revenue CAGR, 3Y
5.4%
Net profit growth, 1Y
7.5%
Free cash flow
$2.3B

Solvency

Current ratio
3.03
Debt / Equity
2.77
Debt / Assets
0.60
CFO / Net profit
1.09
Cash / Market cap
6.9%

Where the revenue went

Of every $100 of FY2025 revenue, $28 was left as net income.

Zoetis Inc. income statement flow, FY2025
Zoetis Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$2.7B
RevenueGross profit$6.8B
Gross profitResearch and development$698.0M
Gross profitSelling, general and administrative$2.4B
Gross profitOther operating expenses$128.0M
Gross profitOperating income$3.6B
Operating incomePretax income$3.4B
Operating incomeInterest and other expense$237.0M
Pretax incomeTax and other$687.0M
Pretax incomeNet income$2.7B

Revenue and net profit

Revenue grew 2.3% in FY2025; net profit is the dashed line.

Zoetis Inc. revenue and net profit by fiscal year
Zoetis Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$8.1B$2.1B
FY2023$8.5B$2.3B
FY2024$9.3B$2.5B
FY2025$9.5B$2.7B

Cash flows

FY2025: $2.9B from operations, $2.3B free after investment (dashed).

Zoetis Inc. operating and free cash flow by fiscal year
Zoetis Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$1.9B$1.3B
FY2023$2.4B$1.6B
FY2024$3.0B$2.3B
FY2025$2.9B$2.3B

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$9.5B+2.3%1Y
EBITDA
$4.1B+5.6%1Y
Net profit
$2.7B+7.5%1Y
Cash from operations
$2.9B-1.7%1Y
Free cash flow
$2.3B-0.7%1Y
Revenue CAGR, 3Y
5.4%
Net profit CAGR, 3Y
8.1%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$9.5B$4.1B$2.7B$2.3B80.2%+2.3%+7.5%

Monthly returns

Month-by-month returns of ZTS across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$15.5B
Liabilities$12.1B
Equity$3.3B
Paid-in capital$1.1B
Retained earnings$13.7B
Treasury stock$10.7B
Minority interest$0.00

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; ZTS highlighted.

P/E against peers

ZTS trades at 12.5x earnings against a peer median of 22.7x (a 45% discount).

Not shown (no positive earnings and no EV / Sales): Centene Corporation.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Zoetis Inc.ZTSthis companyP/E ↓ discount$33.3B12.5x10.0x80.2%9.9x
Agilent Technologies, Inc.A$39.1B30.0x5.8x19.3%22.1x
Waters CorporationWAT$37.0B57.5x14.4x25.1%36.7x
IQVIA Holdings Inc.IQV$31.2B22.9x4.8x20.9%13.0x
Centene CorporationCNC$31.0B-4.6x1.6x-33.4%-6.5x
GE HealthCare Technologies Inc.GEHC$29.0B13.9x2.8x20.1%9.2x
Biogen Inc.BIIB$29.0B22.4x1.6x7.1%12.5x
ResMed Inc.RMD$28.2B20.1x4.7x23.5%14.5x
DexCom, Inc.DXCM$28.0B33.5x10.2x30.5%21.0x
Peer median—22.7x4.8x20.5%13.8x

Year-to-date ROI

ZTS since 1 January, against earlier years.

Historical volatility

ZTS's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Zoetis Inc. operating margin by fiscal year
Zoetis Inc. operating margin by fiscal year
DateOperating margin
FY202236.2%
FY202335.9%
FY202436.6%
FY202538.0%
LineFY2025
Cost of revenueCost Of Revenue$2.7B
Gross profitGross Profit$6.8B
Operating expensesOperating Expense$3.2B
Research and developmentResearch And Development$698.0M
Selling, general and administrativeSelling General And Administration$2.4B
Depreciation and amortisationDepreciation And Amortization In Income Statement$128.0M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$128.0M
Amortization$128.0M
Amortisation of intangiblesAmortization Of Intangibles Income Statement$128.0M
Total expensesTotal Expenses$5.9B
Operating incomeOperating Income$3.6B
Pretax incomePretax Income$3.4B

Learn while you research

Academy chapters picked for Zoetis Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Leverage RatiosDebt/Equity of 2.77 is elevated, understand what that means for solvency.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →